Announcement on Voluntary Disclosure of FDA Orphan Drug Designation for Injectable ZG006 in the Treatment of Neuroendocrine Cancer

About this update from Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A

Announcement on Voluntary Disclosure of FDA Orphan Drug Designation for Injectable ZG006 in the Treatment of Neuroendocrine CancerThe abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A